Faculty profile

Susy Hota

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Susy Hota

Researcher

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
11 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 3 research grants (3 CIHR), most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

203

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Antimicrobial Resistance Clinical Trial Infection Microbiome Fecal Microbiota Transplant Human Intestinal Microbiome Liver Transplant

Latest papers

The Safety, Efficacy, and Feasibility of Fecal Microbiota Transplantation in a Population With Bipolar Disorder During Depressive Episodes: A Pilot Parallel Arm Randomized Controlled Trial: Sécurité, efficacité et faisabilité de la transplantation de microbiote fécal chez une population atteinte de troubles bipolaires, au cours d’épisodes dépressifs : essai pilote contrôlé à répartition aléatoire et à groupes parallèles
Canadian Journal of Psychiatry · 2026
Preparedness for Candida auris in Canadian Nosocomial Infection Surveillance Program (CNISP) hospitals, 2024
Infection Control and Hospital Epidemiology · 2026
Trends in healthcare-associated infections and antimicrobial-resistant organisms among adults in Canadian acute care hospitals: findings from four point prevalence surveys, 2002 to 2024
Infection Control and Hospital Epidemiology · 2025 · senior author

All 26 publications

Latest funding

Strategies for the Treatment and Prevention of Recurrent Clostridioides difficile infection: The SPORES Platform
CIHR · 2025 · Co-investigator
$2,015,775
Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation (ARO-DECAMP)
CIHR · 2022 · Principal investigator
$173,934
Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation (ARO-DECAMP)
CIHR · 2022 · Principal investigator
$695,739

All 7 grants and awards

26 publications.

The Safety, Efficacy, and Feasibility of Fecal Microbiota Transplantation in a Population With Bipolar Disorder During Depressive Episodes: A Pilot Parallel Arm Randomized Controlled Trial: Sécurité, efficacité et faisabilité de la transplantation de microbiote fécal chez une population atteinte de troubles bipolaires, au cours d’épisodes dépressifs : essai pilote contrôlé à répartition aléatoire et à groupes parallèles

Shekarriz S, Vigod SN, Bianco T, Bala A, Hao C, Allard JP, Hota S, Poutanen S, Surette MG, Taylor VH

Canadian Journal of Psychiatry20264 citations

DOI: 10.1177/07067437261420877

Preparedness for Candida auris in Canadian Nosocomial Infection Surveillance Program (CNISP) hospitals, 2024

Tan C, Bharat A, McGill E, Mitchell R, Varsaneux O, Cannon K, Charles MK, Comeau JL, Davis I, Delport J

Infection Control and Hospital Epidemiology20264 citations

DOI: 10.1017/ice.2025.10228

Trends in healthcare-associated infections and antimicrobial-resistant organisms among adults in Canadian acute care hospitals: findings from four point prevalence surveys, 2002 to 2024

Mitchell R, Lee D, Bartoszko J, Lybeck C, Benoit M-È, Comeau J, Ellison J, Frenette C, Happe J, Haslam N

Infection Control and Hospital Epidemiology20254 citationsSenior author

DOI: 10.1017/ice.2025.10259

Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled Trial.

Allegretti JR, Kelly CR, Louie T, Fischer M, Hota S, Misra B, Van Hise NW, Yen E, Bullock JS, Silverman M, Davis I, McGill SK, Pardi DS, Orenstein R, Grinspan A, El-Nachef N, Feuerstadt P, Borody TJ, Khanna S, Budree S, Kassam Z

Gastroenterology2025

DOI: 10.1053/j.gastro.2024.09.030 PMID: 39366468

SARS-CoV-2 infection among physicians over time in Ontario, Canada: a population-based retrospective cohort study.

Habbous S, Saunders N, Chan KK, Hota S, Wang J, Messenger D, Hellsten E

Croatian medical journal2024

DOI: 10.3325/cmj.2024.65.30 PMID: 38433510

First Canadian report of transmission of fluconazole-resistant Candida parapsilosis within two hospital networks confirmed by genomic analysis.

McTaggart LR, Eshaghi A, Hota S, Poutanen SM, Johnstone J, De Luca DG, Bharat A, Patel SN, Kus JV

Journal of clinical microbiology2024

DOI: 10.1128/jcm.01161-23 PMID: 38112529

A microbial consortium alters intestinal Pseudomonadota and antimicrobial resistance genes in individuals with recurrent Clostridioides difficile infection

Rooney AM, Cochrane K, Fedsin S, Yao S, Anwer S, Dehmiwal S, Hota S, Poutanen S, Allen-Vercoe E, Coburn B

mBio202315 citations

DOI: 10.1128/mbio.03482-22

Changes in hospitalizations and emergency department respiratory viral diagnosis trends before and during the COVID-19 pandemic in Ontario, Canada.

Habbous S, Hota S, Allen VG, Henry M, Hellsten E

PloS one2023

DOI: 10.1371/journal.pone.0287395 PMID: 37327212

Hospital outbreak of the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) delta variant in partially and fully vaccinated patients and healthcare workers in Toronto, Canada.

Susky EK, Hota S, Armstrong IE, Mazzulli T, Kestenberg S, Casaubon LK, Granton J, Rebelo C, Bartels E, Wrana J, Vaisman A

Infection control and hospital epidemiology2023

DOI: 10.1017/ice.2021.471 PMID: 34706787

Validation and implementation of group electronic hand hygiene monitoring across twenty-four critical care units

Leis JA, Obaidallah M, Williams V, Muller MP, Powis JE, Johnstone J, Hota S, Katz K, Payne M, Castellani L

Infection Control and Hospital Epidemiology202211 citations

DOI: 10.1017/ice.2021.250

Strategies for the Treatment and Prevention of Recurrent Clostridioides difficile infection: The SPORES Platform

Co-investigatorCIHR2025Project Grant

Principal investigators: McDonald, Emily G; Carignan, Alex; Chan, Adrienne; Chen, Yan; Daley, Peter; Daneman, Nick; Kandel, Christopher; Lee, Todd C; Longtin, Yves; Perez Patrigeon, Santiago; Wuerz, Terence

Keywords: C. Difficile; Clostridioides Difficile Infection; Diarrhea; Fidaxomicin; Nosocomial Infection; Placebo Controlled; Platform Trial; Randomized Controlled Trial; Recurrence; Vancomycin

$2,015,775

Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation (ARO-DECAMP)

Principal investigatorCIHR2022Operating Grant: Clinical Trials Projects - Indirect Costs

Principal investigators: Coburn, Bryan A; Hota, Susy S; Kain, Kevin C; MacFadden, Derek R; Walmsley, Sharon L

Keywords: Antimicrobial Resistance; Clinical Trial; Infection; Microbiome

$173,934

Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation (ARO-DECAMP)

Principal investigatorCIHR2022Operating Grant: Clinical Trials Projects

Principal investigators: Coburn, Bryan A; Hota, Susy S; Kain, Kevin C; MacFadden, Derek R; Walmsley, Sharon L

Keywords: Antimicrobial Resistance; Clinical Trial; Infection; Microbiome

$695,739

Initial vancomycin taper for the prevention of recurrent Clostridium difficile infection

Co-investigatorCIHR2018Project Grant

Principal investigators: Lee, Todd C; McDonald, Emily G

Keywords: Clostridium Dificile; Prevention; Recurrence; Vancomycin

$378,676

CAN-Microbe - The Canadian Microbiome Network

Co-investigatorCIHR2018Canadian Microbiome Initiative 2: Research Core - LOI

Principal investigators: Guttman, David S; Philpott, Dana J

Keywords: Biobanks; Bioethics; Bioinformatics & Data Analysis; Education & Training; Experimental Consultation; Microbial Cultures; Microbiome Research; Mouse Models; Outreach; Standard Operating Procedures

$25,000

Assessing the role and preventative or therapeutic effects of Faecalibacterium prausnitzii and other candidate bacteria in non-alcoholic fatty liver disease

Principal investigatorCIHR2018Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI

Principal investigators: Allard, Johane P; Bhat, Mamatha; Gaisano, Herbert Y; Hota, Susy S; Philpott, Dana J; Poutanen, Susan M

Keywords: Fecal Microbiota Transplant; Human; Intestinal Microbiome; Liver Transplant; Metabolic Syndrome; Mice; Non-Alcoholic Fatty Liver Disease; Nutrition; Prebiotics; Probiotics

$25,000

Exploiting the therapeutic effects of the fecal microbiome in bariatric care

Co-investigatorCIHR2014Team Grant: Bariatric Care - Mechanisms underlying bariatric procedures

Principal investigators: Allard, Johane P; Gaisano, Herbert Y

Keywords: Bariatric Surgery; Fecal Microbiota Transplant; Intestinal Microbiome; Metagenome

$1,375,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2022

Subject: Prospective PhD student: Antimicrobial Resistance Dear Professor Hota, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "The Safety, Efficacy, and Feasibility of Fecal Microbiota Transplantation in a Population With Bipolar Disorder During Depressive Episodes: A Pilot Parallel Arm Randomized Controlled Trial: Sécurité, efficacité et faisabilité de la transplantation de microbiote fécal chez une population atteinte de troubles bipolaires, au cours d’épisodes dépressifs : essai pilote contrôlé à répartition aléatoire et à groupes parallèles" (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation (ARO-DECAMP)" (2022), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Susy Hota

Research

Latest papers

Latest funding

Preparedness for Candida auris in Canadian Nosocomial Infection Surveillance Program (CNISP) hospitals, 2024

Trends in healthcare-associated infections and antimicrobial-resistant organisms among adults in Canadian acute care hospitals: findings from four point prevalence surveys, 2002 to 2024

Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled Trial.

SARS-CoV-2 infection among physicians over time in Ontario, Canada: a population-based retrospective cohort study.

First Canadian report of transmission of fluconazole-resistant Candida parapsilosis within two hospital networks confirmed by genomic analysis.

A microbial consortium alters intestinal Pseudomonadota and antimicrobial resistance genes in individuals with recurrent Clostridioides difficile infection

Changes in hospitalizations and emergency department respiratory viral diagnosis trends before and during the COVID-19 pandemic in Ontario, Canada.

Hospital outbreak of the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) delta variant in partially and fully vaccinated patients and healthcare workers in Toronto, Canada.

Validation and implementation of group electronic hand hygiene monitoring across twenty-four critical care units

Strategies for the Treatment and Prevention of Recurrent Clostridioides difficile infection: The SPORES Platform

Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation (ARO-DECAMP)

Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation (ARO-DECAMP)

Initial vancomycin taper for the prevention of recurrent Clostridium difficile infection

CAN-Microbe - The Canadian Microbiome Network

Assessing the role and preventative or therapeutic effects of Faecalibacterium prausnitzii and other candidate bacteria in non-alcoholic fatty liver disease

Exploiting the therapeutic effects of the fecal microbiome in bariatric care

Frequent collaborators

Dominik Mertz

Allison McGeer

Susan Poutanen

Valerie Taylor

Michelle Science

Amrita Bharat

Erik Hellsten

Michael Silverman

Jennie Johnstone

Tony Mazzulli

Natasha Saunders

Julianne Kus

Lauren Lapointe-Shaw

Shahid Husain

Yves Longtin

Elizabeth Rea

Robert Kozak

Nisha Thampi

Zain Chagla

Deborah Yamamura

John Granton

Monica Taljaard

Michael Surette

Thomas Stewart

Lisa Burry

Bryan Coburn

Emma Allen-Vercoe

Sarah Khan